A voluntary agreement between the Government and the pharmaceutical industry.
The relationship between the pharmaceutical industry and healthcare professionals (HCPs) and healthcare organisations (HCOs) plays a vital role in the development and delivery of life-enhancing and life-saving medicines.
The Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) have welcomed the publication of "Continuity in the availability of goods for the EU and the UK", published today by the UK Government's Department for Exiting the European Union.
As a membership organisation we work with our member companies, and the expertise of the specialists they employ, to develop and present our points of view to UK and European governments, the public and to other stakeholders.
ABPI Chief Executive Stephen Whitehead answers commonly asked questions about clinical trials.
01:02 – Why do pharmaceutical companies run clinical trials and not an independent body or the NHS?
02:08 – Why isn't it a requirement to publish results from both successful and unsuccessful trials?
03:17 – Why do you still bury data to make medicines appear more effective or safer than they are?
04:34 – Why do you still compare medicines against placebo rather than the most effective competitor?
05:57 – How can you justify 'cherry-picking' of data?
06:28 – What is the role of marketing within the pharmaceutical industry and how is this regulated?